In addition, miRNA‐3941, miRNA‐4517 and miRNA‐4672 can reduce the degree of hepatic steatosis through inhibiting the expression of fatty acid binding protein 1 (FABP1), thus delaying the progression of non‐alcoholic fatty liver disease (NAFLD), which is a major catalytic agent of HCC.28, 29 On the other hand, miRNAs also exert crucial roles in regulating the lipid‐metabolizing enzymes through the metabolic‐related transcription factors. This evidence concerns the gene FABP1 and metabolic dysfunction-associated steatotic liver disease.